REG - Feedback PLC - Bleepa wins two NHS Contract Awards

FeedbackAnnouncement

12/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220412:nRSL0271Ia&default-theme=true

RNS Number : 0271I  Feedback PLC  12 April 2022

 

Feedback plc

 

 

Bleepa wins two NHS Contract Awards

 

·      Award of twelve-month contracts with two NHS Trusts, for an
aggregate value of £200,000

 

London, 12 April 2022: Feedback plc (AIM: FDBK, "Feedback" or the "Company"),
the specialist clinical communication company, announces that it has been
awarded two twelve-month contracts to provide its flagship product,
Bleepa(®), across two NHS Trusts, for an aggregate value of £200,000.

 

The first contract follows a successful pilot and co-development on the
platform over the last two years, representing the Company's first full-cycle
realisation of its pilot-to-contract business model.

 

The second represents a contract renewal following the success of an initial
one-year contract, at a higher value than the initial contract.

 

Tom Oakley, CEO of Feedback, said:

 

"We are delighted to see the value of Bleepa as a core clinical system
recognised through the award of two customer contracts. Over the last year we
have significantly grown the number of Bleepa users and it is good to see this
growth recognised in the uplift in contract value achieved. These contracts
are early evidence of the success of our 2019 strategic shift."

 

 

Further information on Feedback and its products can be found on the Company's
website: https://fbkmed.com/feedback-plc/reports-and-presentations/
(https://fbkmed.com/feedback-plc/reports-and-presentations/)

 

-Ends-

 

Enquiries:

 

 Feedback plc                                    +44 (0) 20 3997 7634

 Tom Oakley, CEO                                 IR@fbk.com (mailto:IR@fbk.com)

 Anesh Patel, CFO

 Panmure Gordon (UK) Limited (NOMAD and Broker)  +44 (0)20 7886 2500

 Emma Earl/Freddy Crossley (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Walbrook PR Ltd                                 Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
                                                 (mailto:feedbackplc@walbrookpr.com)
 Paul McManus/Nick Rome/Nicholas Johnson         07980 541 893 or 07748 325 236 or 07884 664 686

 

 

About Feedback

 

Feedback plc is a specialist clinical communications business, with a mission
to improve the efficiency and quality of communications for frontline
clinicians and hospitals with a key focus on building solutions that enhance
access to high quality patient data.

 

Feedback has developed a toolkit of clinical communications apps. Its core,
regulatory approved product is Bleepa, a revolutionary medical imaging app
enabling remote and secure communications between frontline clinicians and
teams. CareLocker is an evolutionary GDPR compliant patient-centric cloud
architecture - its proprietary technology enables an easy route to creation
and mobilisation of individual healthcare records. Bleepa Box is a specialist
tool to enable image transfer from remote settings to the Bleepa platform over
mobile networks.

 

The Company has a number of growth opportunities domestically and
internationally across a range of markets including the NHS, the veterinary
market and private healthcare providers and its highly scalable Software as a
Service ("SaaS")-based revenue model is expected to provide increasing levels
of visibility as the Company grows its customer base.

 

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication
service aimed at assisting listed and unlisted (including AIM quoted)
companies to distribute media only / non-regulatory news releases into the
public domain. Information required to be notified under the AIM Rules for
Companies, Market Abuse Regulation or other regulation would be disseminated
as an RNS regulatory announcement and not on RNS Reach.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCKZGMDVMNGZZM